Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary
D

Dacomitinib

Availability of ACE Drug Guidance

Yes

Biologics Drug Information Overview

No

Subsidy Information and Financing Scheme

Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List

Standard Drug List

Active ingredient: Dacomitinib

General information

Subsidy Information and Financing Scheme

[SDL] Dacomitinib Tablet 15 mg, 30 mg, 45 mg

[MSHL] Dacomitinib Tablet 15 mg, 30 mg, 45 mg

  1. For cancer treatment.

View legend

Drug Guidance for Subsidy

17/8/2021 Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Dacomitinib 15 mg, 30 mg and 45 mg tablets for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer.

Subsidy status

[R] Dacomitinib 15 mg, 30 mg and 45 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) with effect from 3 August 2021.

View legend

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Availability information

Formulation

Public Healthcare Institution

Tablet 15 mg

  1. National Cancer Centre

  2. Ng Teng Fong General Hospital

  3. Tan Tock Seng Hospital

Tablet 30 mg

  1. National Cancer Centre

  2. Ng Teng Fong General Hospital

  3. Tan Tock Seng Hospital

Tablet 45 mg

  1. Ng Teng Fong General Hospital

  2. Tan Tock Seng Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information.

Oral

* Clinical information is available for this product.

Back to top